How to cite item

miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor

   
@article{JTD24752,
	author = {Wei Ma and Weiye Feng and Jie Tan and Airu Xu and Yudong Hu and Lanlan Ning and Yanhong Kang and Liuqian Wang and Ziwen Zhao},
	title = {miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor},
	journal = {Journal of Thoracic Disease},
	volume = {10},
	number = {10},
	year = {2018},
	keywords = {},
	abstract = {Background: Recently, studies have demonstrated that microRNA-497 (miR-497) plays an important role in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in treatment of non-small cell lung cancer (NSCLC) is not fully understood. In this study, we explored the potential of miR-497 in targeting the insulin-like growth factor-1 receptor (IGF-1R) signaling pathways to overcome gefitinib resistance.
Methods: A gefitinib resistant human lung adenocarcinoma A549 cell line (A549/GR) was established by the method of gefitinib mutagenesis culture. Next, the A549/GR cells were transfected with miR-497 mimics to establish an miR-497 overexpression model, designated A549/GR-miR497-mimic. MTT assay was used to assess cell resistance to gefitinib, and western blot assay was employed to evaluate alterations of IGF-1R and the AKT1 signaling pathway.
Results: We found that A549/GR-miR497-mimic cells (IC50 =33.76±0.97 μmol/L) were more sensitive to gefitinib than the control group (P},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/24752}
}